Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet’s syndrome

Elena Silvestri, Alice Bitossi, Alessandra Bettiol*, Giacomo Emmi, Maria Letizia Urban, Irene Mattioli, Gerardo Di Scala, Daniela Bacherini, Giuseppe Lopalco, Vincenzo Venerito, Florenzo Iannone, Antonio Vitale, Gian Marco Tosi, Stanislao Rizzo, Claudia Fabiani, Luca Cantarini, Gianni Virgili, Lorenzo Vannozzi, Domenico Prisco

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Background: To compare the efficacy of Adalimumab (ADA) in noninfectious anterior uveitis (AU) and posterior segment (PS) involvement, associated with different conditions, with a focus on Behçet’s syndrome (BS). Methods: In this retrospective, multicenter post-hoc study, we evaluated the efficacy of ADA in terms of ocular control and relapses in 96 patients with AU and PS uveitis, either idiopathic (IU) or associated with BS or with other systemic disorders (OSD) (Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Vogt-Koyanagi-Harada, Inflammatory Bowel Disease), followed in three tertiary referral centers. Results: Ninety-six patients (45 AU; 51 PS uveitis) were included. Eleven had IU, 58 BS, and 27 OSD. All patients with AU achieved complete long-term ocular control. In PS uveitis, 89%, 67% and 100% of patients with BS, IU and OSD achieved ocular control at the last follow-up (> 12 months), respectively. The lowest ocular relapse rate occurred in patients with AU with BS (1/13) or IU (0/2). ADA accounted for long-term disease control, and no predictors of ocular control and relapse were identified; particularly, ocular relapses seemed not related to systemic ones. Macular edema resolved in 75% and 67% of PS uveitis with BS and IU, respectively. Conclusions: ADA controls both anterior and posterior uveitis, with an efficacy similar in IU, BS and OSD patients. In BS, the efficacy of ADA seems to be independent of demographic and clinical characteristics, and ocular relapses mostly occurred independently from systemic ones. Based on our results, ADA may represent a valid alternative in anterior refractory uveitis.

Original languageEnglish
Pages (from-to)711-718
Number of pages8
JournalInflammopharmacology
Volume28
Issue number3
Early online date10 Mar 2020
DOIs
Publication statusPublished - 01 Jun 2020
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2020, Springer Nature Switzerland AG.

Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.

Keywords

  • Adalimumab
  • Anterior uveitis
  • Behçet’s syndrome
  • Macular edema
  • Ocular relapses
  • Uveitis

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet’s syndrome'. Together they form a unique fingerprint.

Cite this